Literature DB >> 11681994

Enhanced activity of osteoblast differentiation factor (PEBP2alphaA2/CBFa1) in affected sutural osteoblasts from patients with nonsyndromic craniosynostosis.

N K Shevde1, A C Bendixen, M Maruyama, B L Li, D A Billmire.   

Abstract

OBJECTIVE: Nonsyndromic craniosynostosis is characterized by premature closure of one or more cranial sutures in infants. The purpose of this investigation was to evaluate cellular and molecular events that lead to pathogenesis of nonsyndromic craniosynostosis.
DESIGN: This study utilized discarded samples of normal and affected cranial sutures from 12 patients (7 boys, 5 girls) with nonsyndromic craniosynostosis.
RESULTS: Histological evaluation of affected sutures revealed complete osseous obliteration instead of a zone of connective tissue and osteogenic cells as seen in normal sutures. Although proliferation of normal and affected osteoblasts did not vary substantially, elevated osteocalcin production and increased in vitro bone nodule formation indicated that the differentiation and the bone-forming potential of affected osteoblasts was significantly higher than that of normal cells. We therefore investigated the levels and activity of Cbfa1, a transcription factor that plays an integral role in osteoblast differentiation. Northern blot analysis of messenger RNA from both normal and affected sutural osteoblasts revealed a twofold increase in the expression of Cbfa1 in affected cells. This increase in the level of Cbfa1 transcript correlated with an increase in its transcriptional activity on the osteocalcin gene promoter, as assessed using gene transfer methods.
CONCLUSION: Our results indicated that osteoblasts from synostosed sutures exhibit an increased potential for differentiation and bone formation. The increased level and activity of Cbfa1 could play a vital role in the aberrant function of these affected osteoblasts and may explain their altered behavior compared to the normal cells.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2001        PMID: 11681994     DOI: 10.1597/1545-1569_2001_038_0606_eaoodf_2.0.co_2

Source DB:  PubMed          Journal:  Cleft Palate Craniofac J        ISSN: 1055-6656


  5 in total

1.  A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation.

Authors:  Nirupama K Shevde; Lori A Plum; Margaret Clagett-Dame; Hironori Yamamoto; J Wesley Pike; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

2.  ALX4 gain-of-function mutations in nonsyndromic craniosynostosis.

Authors:  Garima Yagnik; Apar Ghuman; Sundon Kim; Christina G Stevens; Virginia Kimonis; Joan Stoler; Pedro A Sanchez-Lara; Jonathan A Bernstein; Cyril Naydenov; Hicham Drissi; Michael L Cunningham; Jinoh Kim; Simeon A Boyadjiev
Journal:  Hum Mutat       Date:  2012-08-13       Impact factor: 4.878

3.  Runx2 protein represses Axin2 expression in osteoblasts and is required for craniosynostosis in Axin2-deficient mice.

Authors:  Meghan E McGee-Lawrence; Xiaodong Li; Krista L Bledsoe; Hai Wu; John R Hawse; Malayannan Subramaniam; David F Razidlo; Bridget A Stensgard; Gary S Stein; Andre J van Wijnen; Jane B Lian; Wei Hsu; Jennifer J Westendorf
Journal:  J Biol Chem       Date:  2013-01-07       Impact factor: 5.157

4.  Advantages of cone beam computed tomography (CBCT) in the orthodontic treatment planning of cleidocranial dysplasia patients: a case report.

Authors:  Domenico Dalessandri; Laura Laffranchi; Ingrid Tonni; Francesca Zotti; Maria Grazia Piancino; Corrado Paganelli; Pietro Bracco
Journal:  Head Face Med       Date:  2011-02-27       Impact factor: 2.151

5.  GLI1 and AXIN2 Are Distinctive Markers of Human Calvarial Mesenchymal Stromal Cells in Nonsyndromic Craniosynostosis.

Authors:  Lorena Di Pietro; Marta Barba; Chiara Prampolini; Sabrina Ceccariglia; Paolo Frassanito; Alessia Vita; Enrico Guadagni; Davide Bonvissuto; Luca Massimi; Gianpiero Tamburrini; Ornella Parolini; Wanda Lattanzi
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.